Logo image of SBC

SBC MEDICAL GROUP HOLDINGS I (SBC) Stock Fundamental Analysis

NASDAQ:SBC - Nasdaq - US73245B1070 - Common Stock - Currency: USD

4.64  0 (0%)

After market: 4.64 0 (0%)

Fundamental Rating

6

Taking everything into account, SBC scores 6 out of 10 in our fundamental rating. SBC was compared to 103 industry peers in the Health Care Providers & Services industry. SBC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SBC has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year SBC was profitable.
SBC had a positive operating cash flow in the past year.
SBC Yearly Net Income VS EBIT VS OCF VS FCFSBC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M 80M

1.2 Ratios

SBC has a better Return On Assets (17.34%) than 96.12% of its industry peers.
The Return On Equity of SBC (21.80%) is better than 88.35% of its industry peers.
With an excellent Return On Invested Capital value of 28.47%, SBC belongs to the best of the industry, outperforming 97.09% of the companies in the same industry.
Industry RankSector Rank
ROA 17.34%
ROE 21.8%
ROIC 28.47%
ROA(3y)11.06%
ROA(5y)N/A
ROE(3y)17.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SBC Yearly ROA, ROE, ROICSBC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 20 30

1.3 Margins

SBC has a Profit Margin of 24.94%. This is amongst the best in the industry. SBC outperforms 100.00% of its industry peers.
The Operating Margin of SBC (43.00%) is better than 100.00% of its industry peers.
SBC's Gross Margin of 77.94% is amongst the best of the industry. SBC outperforms 92.23% of its industry peers.
Industry RankSector Rank
OM 43%
PM (TTM) 24.94%
GM 77.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SBC Yearly Profit, Operating, Gross MarginsSBC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 20 40 60

More info and screens

9

2. Health

2.1 Basic Checks

SBC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, SBC has less shares outstanding
The debt/assets ratio for SBC has been reduced compared to a year ago.
SBC Yearly Shares OutstandingSBC Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M 80M 100M
SBC Yearly Total Debt VS Total AssetsSBC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 8.38 indicates that SBC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.38, SBC belongs to the top of the industry, outperforming 93.20% of the companies in the same industry.
The Debt to FCF ratio of SBC is 0.56, which is an excellent value as it means it would take SBC, only 0.56 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.56, SBC belongs to the top of the industry, outperforming 89.32% of the companies in the same industry.
SBC has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
SBC has a Debt to Equity ratio of 0.03. This is in the better half of the industry: SBC outperforms 79.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.56
Altman-Z 8.38
ROIC/WACC3.27
WACC8.72%
SBC Yearly LT Debt VS Equity VS FCFSBC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

SBC has a Current Ratio of 4.44. This indicates that SBC is financially healthy and has no problem in meeting its short term obligations.
SBC has a Current ratio of 4.44. This is amongst the best in the industry. SBC outperforms 93.20% of its industry peers.
A Quick Ratio of 4.40 indicates that SBC has no problem at all paying its short term obligations.
SBC has a better Quick ratio (4.40) than 93.20% of its industry peers.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.4
SBC Yearly Current Assets VS Current LiabilitesSBC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 383.61% over the past year.
Looking at the last year, SBC shows a very strong growth in Revenue. The Revenue has grown by 261.14%.
EPS 1Y (TTM)383.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.16%
Revenue 1Y (TTM)261.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-13.65%

3.2 Future

SBC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.24% yearly.
SBC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y8.4%
EPS Next 2Y9.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.42%
Revenue Next 2Y1.15%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

SBC Yearly Revenue VS EstimatesSBC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 50M 100M 150M 200M
SBC Yearly EPS VS EstimatesSBC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.2 0.4 0.6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.09 indicates a reasonable valuation of SBC.
Compared to the rest of the industry, the Price/Earnings ratio of SBC indicates a rather cheap valuation: SBC is cheaper than 92.23% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.15, SBC is valued rather cheaply.
The Price/Forward Earnings ratio is 6.47, which indicates a rather cheap valuation of SBC.
SBC's Price/Forward Earnings ratio is rather cheap when compared to the industry. SBC is cheaper than 98.06% of the companies in the same industry.
SBC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.60.
Industry RankSector Rank
PE 10.09
Fwd PE 6.47
SBC Price Earnings VS Forward Price EarningsSBC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SBC is valued cheaper than 96.12% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as SBC.
Industry RankSector Rank
P/FCF 31.28
EV/EBITDA 4.04
SBC Per share dataSBC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.2
PEG (5Y)N/A
EPS Next 2Y9.24%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SBC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SBC MEDICAL GROUP HOLDINGS I

NASDAQ:SBC (6/30/2025, 4:30:02 PM)

After market: 4.64 0 (0%)

4.64

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)09-21 2025-09-21
Inst Owners0.09%
Inst Owner ChangeN/A
Ins Owners89.47%
Ins Owner Change0%
Market Cap480.75M
AnalystsN/A
Price Target6.13 (32.11%)
Short Float %0.72%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.84%
Min EPS beat(2)10.66%
Max EPS beat(2)89.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.84%
Min Revenue beat(2)-22.64%
Max Revenue beat(2)-9.04%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.17%
PT rev (3m)-39.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)43.33%
EPS NY rev (3m)-9.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.13%
Revenue NY rev (1m)0.46%
Revenue NY rev (3m)-22.75%
Valuation
Industry RankSector Rank
PE 10.09
Fwd PE 6.47
P/S 2.43
P/FCF 31.28
P/OCF 25.53
P/B 2.12
P/tB 2.18
EV/EBITDA 4.04
EPS(TTM)0.46
EY9.91%
EPS(NY)0.72
Fwd EY15.45%
FCF(TTM)0.15
FCFY3.2%
OCF(TTM)0.18
OCFY3.92%
SpS1.91
BVpS2.19
TBVpS2.12
PEG (NY)1.2
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.34%
ROE 21.8%
ROCE 36.04%
ROIC 28.47%
ROICexc 64.59%
ROICexgc 68.77%
OM 43%
PM (TTM) 24.94%
GM 77.94%
FCFM 7.76%
ROA(3y)11.06%
ROA(5y)N/A
ROE(3y)17.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.56
Debt/EBITDA 0.08
Cap/Depr 101.52%
Cap/Sales 1.75%
Interest Coverage 2701.71
Cash Conversion 21.27%
Profit Quality 31.14%
Current Ratio 4.44
Quick Ratio 4.4
Altman-Z 8.38
F-Score6
WACC8.72%
ROIC/WACC3.27
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)383.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.16%
EPS Next Y8.4%
EPS Next 2Y9.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)261.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-13.65%
Revenue Next Year-9.42%
Revenue Next 2Y1.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y268.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1908.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2315.21%
OCF growth 3YN/A
OCF growth 5YN/A